ArticleFrontiers in pharmacology2026
Acute post-infusion hypokalemia following rituximab therapy in patients with nephrotic syndrome: case series and literature review.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rituximab has become an important therapeutic option for nephrotic syndrome (NS), and its adverse event profile is generally well characterized. However, reports of acute hypokalemia specifically occurring in the post-infusion period remain rare. We aimed to present and analyze cases of this distinct timing of electrolyte disturbance. Case Presentation: This case series describes two adult patients with NS who developed acute, severe hypokalemia in the hours immediately following a rituximab infusion. Case 1: A 20-year-old male with steroid-dependent minimal change disease developed progressive quadriceps weakness and severe hypokalemia (potassium 1.79 mmol/L) several hours after his fifth rituximab infusion. His previous four infusions had been uneventful. Case 2: A 46-year-old male with membranous nephropathy presented with marked mental fatigue and severe hypokalemia (potassium 2.34 mmol/L) shortly after his sixth cumulative rituximab infusion, following five prior tolerated infusions. Common precipitants of hypokalemia were absent. Both patients responded promptly to potassium supplementation, with full symptomatic recovery and normalization of serum potassium. Conclusion: Severe hypokalemia can occur acutely after rituximab infusion in NS, even after prior uneventful exposures. Presentations may be delayed and nonspecific. Clinicians should monitor serum potassium before and after rituximab administration to enable timely recognition and management of this rare complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.